COX-2 inhibitors in prostate cancer treatment--hold your horses?
Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Vic. 3084, Australia.
Ada S
AS
Cheung
Mathis
M
Grossmann
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D017430:Prostate-Specific Antigen; D000068579:Celecoxib